Immune anticancer drug composition using lipopeptide and poly(I:C) adjuvant
A combination of lipopeptide, poly(I:C) adjuvant, and immune checkpoint inhibitors or TLR ligands enhances cancer-specific immune responses, addressing the limitations of existing immune checkpoint inhibitors by increasing antigen exposure and immune cell infiltration, thereby improving cancer treatment efficacy.
Patent Information
- Application Number
- KR1020220063211
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-05-24
- Filing Date
- 2022-05-24
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2042-05-24
AI Technical Summary
Existing immune checkpoint inhibitors show limited efficacy due to low response rates and resistance in cancer treatment, primarily because of varying immune checkpoint protein expression levels and low exposure to cancer antigens, leading to ineffective immune responses.
A combination formulation comprising a lipopeptide, a poly(I:C) adjuvant, and additional components like immune checkpoint inhibitors or TLR ligands to enhance cancer-specific immune responses and overcome immune evasion mechanisms.
The combination formulation induces potent anticancer effects by increasing cancer antigen exposure, enhancing immune cell infiltration, and activating immune responses, significantly reducing tumor size and improving treatment outcomes.
Smart Images

Figure 112022054603983-PAT00002_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to an immuno-oncology therapeutic composition comprising a lipopeptide and a poly(I:C) adjuvant as active ingredients.
[0002] In addition, the present invention relates to an immunotherapeutic agent composition that increases anticancer immune activity by co-administering an immune checkpoint inhibitor or another TLR ligand to a lipopeptide and a poly(I:C) adjuvant. Background Technology
[0004] Toll-like receptors (TLRs) are cell receptors that induce innate immune responses. They recognize pathogen-associated molecular patterns (PAMPs) derived from early pathogens and activate innate immune defense mechanisms through signaling pathways, playing a role in defending against pathogen invasion from the initial stages. Furthermore, they perform important immune functions by activating dendritic cells and even adaptive immune responses involving T cells and B cells.
[0005] TLRs, which are known to be expressed in most immune cells, are also known to be expressed in various cancer cells (Non-patent literature 1, Cancer Microenvironment (2009) 2 (Suppl 1):S205-S214, Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment).
[0006] Type of cancer TLR Gastric cancer TLR2, TLR4, TLR5, TLR9 Colorectal cancer TLR2, TLR3, TLR4, TLR5, TLR9 Ovarian cancer TLR2, TLR3, TLR4, TLR5 Cervical cancer TLR3, TLR4, TLR5, TLR9 Lung cancer TLR2, TLR3, TLR4, TLR9 Prostate cancer TLR4, TLR9 Melanomas TLR2, TLR3, TLR4 Brain cancer TLR2, TLR4 Brest cancer TLR2, TLR3, TLR4, TLR9 Hepatocellular carcinoma TLR2, TLR3, TLR4, TLR6, TLR9 Laryngeal cancer TLR2, TLR3, TLR4
[0007] TLRs expressed on cancer cells can enhance immune responses in the tumor microenvironment by inducing the invasion of immune cells into cancer cells through the secretion of cytokines and chemokines.
[0008] In addition, it has been reported that direct treatment of cancer cells with TLR stimulating substances (TLR ligands) induces apoptosis. TLR ligands induce apoptosis in cancer cells by activating the caspase pathway within the cells, thereby causing cell death, and Type I IFN activated by TLR ligands further promotes apoptosis through the activation of immune cells.
[0009] When cancer cells are killed by TLR ligands, endogenous proteins and immunogenic cell death markers are secreted from the dead cancer cells, and dendritic cells are activated by these factors, and cancer cell-specific NK cells and T cells play a role in killing the cancer cells.
[0010] In addition, when cancer cells are killed by TLR ligands, it promotes the exposure of cancer antigens derived from the cancer cells and the secretion of DAMPs (Damage associated molecular patterns), and the exposed cancer antigens can induce a cancer antigen-specific immune response through the adjuvant effect of TLR ligands. Therefore, TLR ligands are expected to be developed as immunotherapies by inducing cancer cell death and a cancer antigen-specific immune response.
[0011] Immune checkpoint proteins are cell membrane proteins that function to inhibit the differentiation, proliferation, and activity of immune cells, but they are expressed not only in immune cells but also in cancer cells. Immune checkpoint proteins expressed in cancer cells, such as PD-L1, are known to induce immune evasion mechanisms in cancer by performing an important role in protecting cancer cells from T-cell immune attacks through the inactivation of cancer-specific T cells. Immune checkpoint inhibitors help immunotherapies eliminate cancer cells by inhibiting the function of these immune checkpoint proteins.
[0012] It is known that when used as monotherapy, immune checkpoint inhibitors show high therapeutic efficacy in about 30% of patients, but are ineffective in the remaining patients. The reason for this limited efficacy of immune checkpoint inhibitors is known to be due to low response rates and resistance to the drugs.
[0013] The low response rate of immune checkpoint inhibitors is attributed to the fact that the expression levels of immune checkpoint proteins vary by cancer type, resulting in low response rates in cancer types with low expression levels. Furthermore, even if evasion mechanisms are suppressed by immune checkpoint inhibitors, the low response rate persists because the limited exposure to cancer antigens prevents the induction of cancer-specific immune responses capable of killing cancer cells. Therefore, the limitations of immune checkpoint inhibitors can be overcome by employing methods that increase exposure to cancer antigens and enhance cancer-specific immune responses.
[0014] Resistance to immune checkpoint inhibitors occurs because tumor-specific immune cells do not enter the cancer tissue, forming an early low-immunogenic environment without immune cell infiltration, which leads to resistance to immunotherapy.
[0015] To overcome the low response rates and resistance of these immune checkpoint inhibitors, a method to convert a low-immunogenic tumor environment into a high-immunogenic tumor environment is required, and this can be expected to be resolved through immunogenicity enhancement using TLR ligands.
[0016] In prior research, the inventors developed a vaccine composition comprising a lipopeptide, which is a TLR2 ligand, and a poly(I:C), which is a TLR3 ligand, and confirmed that said vaccine composition induces a strong immune response (Korean Registered Patent No. 10-0900837, Korean Registered Patent No. 10-1501583), and named said vaccine composition L-pampo.
[0017] In this invention, the researchers discovered that L-Pampo induces a potent immuno-anticancer response and confirmed that administering L-Pampo to tumor cells inhibits the growth of cancer cells, induces apoptosis, and inhibits metastasis by utilizing the anticancer effect caused by changes in the tumor microenvironment and the effect of inducing a cancer antigen-specific immune response. Furthermore, the researchers completed this invention by confirming that administering L-Pampo in combination with other TLR ligands, saponins, or immune checkpoint inhibitors overcomes the immune evasion of cancer cells and dramatically improves anticancer efficacy. The problem to be solved
[0019] An objective of one aspect of the present invention is,
[0020] The present invention provides a pharmaceutical composition for the prevention or treatment of cancer comprising a lipopeptide and a poly(I:C) adjuvant as active ingredients.
[0021] An object in another aspect of the present invention is,
[0022] The present invention provides a method for generating an immune response against cancer in an individual other than a human, comprising the step of administering a pharmaceutical composition for the prevention or treatment of cancer, comprising lipopeptide and poly(I:C) as active ingredients, to said individual.
[0023] An object in another aspect of the present invention is,
[0024] The present invention provides a combination formulation for the prevention or treatment of cancer comprising a lipopeptide, a poly(I:C) adjuvant, and an immune checkpoint inhibitor as active ingredients.
[0025] An object in another aspect of the present invention is,
[0026] The present invention provides a combination formulation for the prevention or treatment of cancer comprising a lipopeptide, a poly(I:C) adjuvant, and a TLR ligand as active ingredients.
[0027] The present invention provides a combination formulation for the prevention or treatment of cancer comprising a lipopeptide, a poly(I:C) adjuvant, and a saponin as active ingredients. means of solving the problem
[0029] In order to achieve the above objective,
[0030] One aspect of the present invention is,
[0031] A pharmaceutical composition for the prevention or treatment of cancer is provided, comprising lipopeptide and poly(I:C) as active ingredients.
[0032] In addition, another aspect of the present invention is,
[0033] A method for generating an immune response against cancer in an individual other than a human is provided, comprising the step of administering a pharmaceutical composition for the prevention or treatment of cancer, comprising lipopeptide and poly(I:C) as active ingredients, to said individual.
[0034] In addition, another aspect of the present invention is,
[0035] A combination formulation for the prevention or treatment of cancer is provided, comprising a lipopeptide, a poly(I:C) adjuvant, and an immune checkpoint inhibitor as active ingredients.
[0036] In addition, another aspect of the present invention is,
[0037] A combination formulation for the prevention or treatment of cancer is provided, comprising a second component including a lipopeptide, a poly(I:C) adjuvant, and a TLR (Toll-like receptor) ligand as active ingredients.
[0038] Furthermore, another aspect of the present invention is,
[0039] A combination formulation for the prevention or treatment of cancer is provided, comprising a lipopeptide, a poly(I:C) adjuvant, and a saponin as active ingredients. Effects of the invention
[0041] An immunotherapeutic agent composition comprising a lipopeptide and a poly(I:C) adjuvant as active ingredients, provided in one aspect of the present invention, can induce a high therapeutic effect against various types of cancer and significantly enhances the anticancer effect through co-administration with existing anticancer agents such as chemotherapy agents, anticancer vaccines, and immune checkpoint inhibitors with different mechanisms. Brief explanation of the drawing
[0043] Figure 1 is a figure confirming the Caspase-3 activity of an immunotherapy drug in mouse colon cancer cell lines. Figure 2 is a figure confirming the tumor-suppressing efficacy of an immunotherapy drug in a melanoma tumor mouse model. Figure 3 is a figure confirming the tumor-suppressing efficacy of an immunotherapy drug in a colorectal cancer tumor mouse model. Figure 4 is a figure analyzing the efficacy of immunotherapeutic agents in infiltrating immune cells within tumors using immunofluorescence staining in a colorectal cancer tumor mouse model. Figure 5 is a figure showing the analysis of the efficacy of an immunotherapy drug in infiltrating immune cells within a tumor using a flow cytometer in a colorectal cancer tumor mouse model. Figure 6 is a figure analyzing the induction of tumor-specific cellular immune responses by immunotherapies using ELISPOT analysis in a colorectal cancer tumor mouse model. Figure 7 is a figure analyzing the efficacy of an immunotherapy drug in a colorectal cancer tumor mouse model. Figure 8 is a figure confirming the tumor-suppressing efficacy of an immunotherapy drug in a bladder cancer mouse model. Figure 9 is a figure confirming the tumor-suppressing efficacy of an immunotherapy drug in a pancreatic cancer mouse model. Figure 10 is a figure confirming the efficacy of combining an immunotherapy drug with an immune checkpoint inhibitor in a colorectal cancer mouse model. Figure 11a is a figure confirming the efficacy (tumor size) of an immunotherapy drug in combination with other TLR ligands or saponins in a colorectal cancer mouse model. Figure 11b shows the efficacy (tumor weight) of an immunotherapy drug combined with other TLR ligands or saponins in a colorectal cancer mouse model. Specific details for implementing the invention
[0044] The present invention will be described in detail below.
[0045] Meanwhile, embodiments of the present invention may be modified in various other forms, and the scope of the present invention is not limited to the embodiments described below. Furthermore, embodiments of the present invention are provided to more completely explain the present invention to those with average knowledge in the relevant technical field.
[0046] Furthermore, throughout the specification, the term "comprising" a component means that, unless specifically stated otherwise, it does not exclude other components but rather may include additional components.
[0047] One aspect of the present invention is,
[0048] A pharmaceutical composition for the prevention or treatment of cancer is provided, comprising lipopeptide and poly(I:C) as active ingredients.
[0049] The above lipopeptide is a synthetic analogue of lipopeptides derived from bacteria and mycoplasma, and was first synthesized by J. Metzger et al. (Metzger, J. et al., 1991, Synthesis of novel immunologically active tripalmitoyl-S-glycerylcysteinyl lipopeptides as useful intermediates for immunogen preparations. Int. J. Peptide Protein Res. 37: 46-57). The molecular structure of the compound represented by the following chemical formula (1) is N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-[R]-cystein-SKKKK(pam3Cys-SKKKK), and various other analogs have been synthesized.
[0050] [Chemical Formula (1)]
[0051]
[0052] According to H. Schild et al., when Pam3Cys-Ser-Ser was combined with an influenza virus T cell epitope and administered to mice, virus-specific cytotoxic T lymphocytes (CTLs) were induced. Lipopeptides are generally known as ligands for TLR2. The use of such lipopeptides is not limited to Pam3Cys-SKKKK, and lipopeptides can be composed of a fatty acid bound to a glycerol molecule and various amino acids. Specific examples include PHC-SKKKK, Ole2PamCys-SKKKK, Pam2Cys-SKKKK, PamCys(Pam)-SKKKK, Ole2Cys-SKKKK, Myr2Cys-SKKKK, PamDhc-SKKKK, PamCSKKKK, Dhc-SKKKK, etc. The number of fatty acids within the molecule may be one or more. The number of amino acids in the lipopeptide may be one or more. Additionally, fatty acids and amino acids may be chemically modified. Furthermore, the lipopeptide may be a lipoprotein in the form of a molecule or a whole molecule derived from Gram-positive or Gram-negative bacteria or Mycoplasma.
[0053] Furthermore, the aforementioned poly(I:C) has been used as a potent derivative of type 1 interferon in in vitro and in vivo studies. Moreover, poly(I:C) is known to stably and maturely form dendritic cells, which are the most potent antigen-presenting cells in mammals (Rous, R. et al 2004. poly(I:C) used for human dendritic cell maturation preserves their ability to secondarily secrete bioactive IL-12, International Immunol. 16: 767-773). According to these previous reports, poly(I:C) is a potent IL-12 inducer, and IL-12 is an important cytokine that drives the immune response to Th1 development, thereby inducing a cellular immune response and the formation of IgG2a or IgG2b antibodies. In addition, poly(I:C) is known to have potent adjuvant activity against peptide antigens (Cui, Z. and F. Qui. 2005. Synthetic double stranded RNA poly I:C as a potent peptide vaccine adjuvant: Therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol. Immunotherapy 16: 1-13). Poly(I:C) is known as a representative TLR3 ligand. Poly(I:C) may have a length in the range of 50 to 5,000 bp, and is preferably 50 to 2,000 bp, and is preferably 100 to 500 bp, but is not particularly limited thereto.
[0054] The above lipopeptide and poly(I:C) may be included in the pharmaceutical composition in a weight ratio of 0.1 to 10:1, 1.25 to 2:1, 1.25 to 1.5:1, or 1.25:1, but are not particularly limited thereto and can be adjusted to an appropriate level depending on the patient's condition. In addition, the above pharmaceutical composition may be in an aqueous solution form.
[0055] The above pharmaceutical composition may further comprise one or more selected from the group consisting of pharmaceutically acceptable carriers, diluents, and adjuvants. For example, the above pharmaceutical composition may comprise a pharmaceutically acceptable carrier and may be formulated for human or veterinary use and administered via various routes. The routes of administration may include oral, intraperitoneal, intravenous, intramuscular, subcutaneous, intradermal, etc. Preferably, it is administered by formulation as an injectable. The injectable preparation can be prepared using aqueous solvents such as physiological saline solution or Ringer's solution, vegetable oils, higher fatty acid esters (e.g., ethyl oleate), alcohols (e.g., ethanol, benzyl alcohol, propylene glycol, glycerin, etc.), non-aqueous solvents such as vegetable oil, higher fatty acid esters (e.g., ethyl oleate), alcohols (e.g., ethanol, benzyl alcohol, propylene glycol, glycerin, etc.), and may include a pharmaceutical carrier such as a stabilizer to prevent deterioration (e.g., ascorbic acid, sodium bisulfite, sodium pyrosulfite, BHA, tocopherol, EDTA, etc.), an emulsifier, a buffer to adjust pH, or a preservative to inhibit microbial growth (e.g., phenylmercury nitrate, thimerosal, benzalkonium chloride, phenol, cresol, benzyl alcohol, etc.). The above pharmaceutical composition may be administered in a pharmaceutically effective amount. At this time, the term "pharmaceutical effective dose" means a sufficient amount to produce an immuno-anticancer effect and an amount that does not cause side effects or serious or excessive immune responses, and the exact dosage concentration varies depending on the composition to be administered and can be easily determined by a person skilled in the art based on factors well known in the medical field, such as the patient's age, weight, health, gender, sensitivity to the drug, route of administration, and method of administration, and can be administered once or several times.
[0056] Another aspect of the present invention is,
[0057] A method for generating an immune response against cancer in an individual other than a human is provided, comprising the step of administering a pharmaceutical composition for the prevention or treatment of cancer, comprising lipopeptide and poly(I:C) as active ingredients, to said individual.
[0058] However, if the above pharmaceutical composition is administered to a human (patient), it may be administered in an amount effective for stimulating an in vivo immune response, for example, to a human once or several times, and the dosage may be 0.25-3.6 mg, more preferably 0.45-1.8 mg, but is not particularly limited thereto.
[0059] Another aspect of the present invention is,
[0060] The present invention provides a pharmaceutical combination formulation for the prevention or treatment of cancer, comprising a lipopeptide, poly(I:C), and an immune checkpoint inhibitor as active ingredients.
[0061] At this time, the above immune checkpoint inhibitor is,
[0062] One or more selected from the group consisting of anti-CTLA4 antibodies, anti-PD-L1 antibodies, and anti-PD-1 antibodies may be used.
[0063] More specifically, the immune checkpoint inhibitor may be selected from anti-CTLA4 antibody, its derivative, or its antigen-binding fragment; anti-PD-L1 antibody, its derivative, or its antigen-binding fragment; anti-LAG-3 antibody, its derivative, or its antigen-binding fragment; anti-OX40 antibody, its derivative, or its antigen-binding fragment; anti-TIM3 antibody, its derivative, or its antigen-binding fragment; and anti-PD-1 antibody, its derivative, or its antigen-binding fragment. As a specific example, Yervoy (ipilimumab) may be used as an immune checkpoint inhibitor targeting CTLA-4; and Tecentriq (atezolizumab), Avelumab (Bavencio), Imfinzi (durvalumab), etc., which target PD-L1, may be used alone or in combination of two or more. PD-1 targeting immune checkpoint inhibitors such as Keytruda (pembrolizumab), Opdivo (nivolumab), and Libtayo (cemiflimab) can be used alone or in combination of two or more.
[0064] Another aspect of the present invention is,
[0065] The present invention provides a combination formulation for the prevention or treatment of cancer comprising a lipopeptide and poly(I:C) and TLR (Toll-like receptor) ligands as active ingredients.
[0066] At this time, the TLR (Toll-like receptor) ligand may be one or more ligands selected from TLR 1 to 13. As specific examples, a TLR7 ligand (Imiquimod et al.), a TLR7 / 8 ligand (Imidazoquinoline et al.), and a TLR9 ligand (CpG ODN et al.) may be used.
[0067] Another aspect of the present invention is,
[0068] A combination formulation for the prevention or treatment of cancer is provided, comprising lipopeptide, poly(I:C), and saponin as active ingredients.
[0069] At this time, the saponin may be selected from the group consisting of QS21, Quil A, QS7, QS17, and combinations thereof.
[0070] An immunotherapeutic agent composition comprising a lipopeptide and a poly(I:C) adjuvant as active ingredients, provided in one aspect of the present invention, can induce a high therapeutic effect against various types of cancer and significantly enhances the anticancer effect through co-administration with existing anticancer agents such as chemotherapy agents, anticancer vaccines, and immune checkpoint inhibitors with different mechanisms.
[0071] Specifically, it was confirmed that the immunotherapeutic agent composition comprising the lipopeptide and poly(I:C) of the present invention (hereinafter, L-pampo) can induce apoptosis in cancer cells by more activating Capspase-3 of the caspase pathway within cancer cells than when the lipopeptide or poly(I:C) is treated alone (see FIG. 1). Accordingly, it was confirmed that L-pampo most strongly induces apoptosis in colon cancer cells.
[0072] In addition, it was confirmed that L-pampo reduced tumor size in a melanoma mouse model (see Fig. 2), and it was also confirmed that L-pampo reduced tumor size in a colorectal cancer mouse model, indicating its anticancer efficacy (see Fig. 3). Furthermore, it was confirmed that the L-pampo of the present invention induces immune activity capable of killing tumors by inducing the infiltration of many CD8 T cells into the tumor of a colorectal cancer mouse model and inhibiting Treg+ cells (see Figs. 4 and 5).
[0073] In addition, it was confirmed that the L-pampo of the present invention strongly induces a tumor-specific cellular immune response by increasing the secretion of IFN-γ in a colorectal cancer tumor mouse model (see Fig. 6). Furthermore, it was confirmed that the L-pampo of the present invention has an abscopal effect of reducing the size of tumors administered with L-pampo as well as tumors not administered with L-pampo (see Fig. 7).
[0074] Meanwhile, it was confirmed that L-pampo reduced the size of tumors in a bladder cancer mouse model (see Fig. 8), and it was also confirmed that L-pampo reduced the size of tumors in a pancreatic cancer mouse model (see Fig. 9). The above results suggest that the L-pampo of the present invention exhibits anticancer efficacy in various cancers.
[0075] Meanwhile, it was confirmed that when the L-pampo of the present invention was administered in combination with the immune checkpoint inhibitor PD-1 antibody, the tumor size was significantly reduced compared to the single treatment group (see Fig. 10). Therefore, combination therapy with L-pampo and an immune checkpoint inhibitor suggests that there is a potent anticancer effect. In addition, it was confirmed that when the L-pampo of the present invention was administered in combination with another TLR ligand (imiquimod) or saponin (QS-21), the tumor size and weight were significantly reduced compared to the single treatment group (see Figs. 11a and 11b). Therefore, it was confirmed that combination therapy with the immuno-anticancer agent L-pampo of the present invention and other TLR ligands or saponins can exhibit a synergistic effect and show a potent anticancer effect.
[0076] The L-pampo comprising the lipopeptide and poly(I:C) of the present invention exhibited potent anticancer efficacy by inducing a cancer-specific cellular immune response, infiltrating a large number of CD8+ T cells into the tumor, and strongly inhibiting tumor growth. Through this, it was confirmed that the intratumoral administration of an immunotherapeutic composition containing L-pampo can be used as an immunotherapeutic agent that kills cancer cells and demonstrates potent anticancer efficacy through a cancer-specific immune response and the infiltration of immune cells into the tumor.
[0077] The present invention will be explained in detail below through examples and experimental examples.
[0078] However, the following examples and experimental examples are merely illustrative of the present invention, and the content and scope of the present invention are not limited to the following.
[0079] [Example 1] Analysis of caspase-3 activity of immunotherapeutic agents containing lipopeptide and poly(I:C) in colorectal cancer cell line MC38 cells
[0080] [1-1] Cell Seeding and Stimulation
[0081] 1.5 × 10⁴ colorectal cancer cell line MC38 cells in a 12-well culture plate 5 After seeding cells / wells, on the next day, L-pampo mixed with TLR2 ligand (Pam3CSK4), TLR3 ligand (Poly(I:C)), or TLR2 (Pam3CSK4) and TLR3 ligand (Poly(I:C)) was treated and cultured for 24 hours. At this time, L-pampo was prepared by mixing 50 µg of TLR2 ligand (Pam3CSK4) and 40 µg of TLR3 ligand (Poly(I:C)).
[0083] [1-2] Preparation of cell extract
[0084] Once 24 hours of stimulation are complete, the cells are harvested, resuspended in approximately 100 μL of lysis buffer, and incubated on ice for 5 minutes. After centrifugation at 1000×g for 10 minutes at 4°C, the lysate from the supernatant is taken and transferred to a new e-tube. The concentration of each sample is measured using BCA analysis, and the concentrations of all samples are equalized. This cell extract sample is stored at 4°C for immediate use and at -20°C for long-term storage.
[0086] [1-3] Analysis of Caspase-3 Cell Activity
[0087] The analysis was performed according to the instructions of the caspase-3 cell activity assay kit (Millipore, #235419). Cell extracts from the blank, negative control (cell extract treated with a caspase-3 inhibitor), positive control (purified caspase-3), and each sample were reacted with a caspase substrate (Ac-DEVD-pNA), and OD (405 nm) values were measured via color development at intervals of 5 to 10 minutes for a minimum of 30 minutes to a maximum of 120 minutes. The conversion factor was calculated using a substrate standard, and the activity of each sample was expressed as p mol / min.
[0089] [1-4] Comparative analysis of Caspase-3 activity
[0090] The activity of caspase-3 was compared and analyzed in cell extract samples treated with negative and positive controls, TLR2 ligands, TLR3 ligands, and L-pampo.
[0091] The results are shown in Figure 1. Figure 1 is a figure confirming the Caspase-3 activity of an immunotherapy drug in mouse colon cancer cell lines.
[0092] As shown in Figure 1, it was confirmed that L-pampo most strongly induces apoptosis in colorectal cancer cell line MC38 cells by confirming that caspase-3 activity was induced relatively higher in the experimental group treated with L-pampo compared to the experimental groups treated with TLR2 ligand and TLR3 ligand.
[0094] [Example 2] Confirmation of efficacy of an immuno-oncology agent containing lipopeptide and poly(I:C) in a melanoma mouse model
[0095] [2-1] Creation of a Melanoma Tumor Mouse Model
[0096] 2×10 on the right side of 7-week-old female C57BL / 6 mice (Orient Bio, Korea) 5 Tumors were induced in mice by subcutaneously injecting the B16F10 mouse melanoma cell line.
[0098] [2-2] Preparation and Administration of Immunotherapy Agents
[0099] The immunotherapeutic agent L-pampo was prepared by mixing 50 µg of Pam3CSK4 and 40 µg of poly(I:C). A buffer administration group was established as a negative control, and the tumor size of the melanoma tumor mouse model constructed in [2-1] was approximately 100 mm 3 When it was reached, 90 µg / dose of L-pampo was administered into the tumor three times at 3-day intervals.
[0101] [2-3] Analysis of Tumor Suppressive Efficacy
[0102] Tumor size of all experimental groups was measured at intervals of 2 to 3 days. The length and short axis of the tumor were measured [1 / 2 × length of the long axis × (length of the short axis) 2 The tumor size was calculated using ]. The tumor-suppressing efficacy of the immuno-oncology drug was analyzed based on the calculated tumor size.
[0103] The results are shown in Fig. 2. Fig. 2 is a figure confirming the tumor-suppressing efficacy of an immunotherapy drug in a melanoma tumor mouse model.
[0104] As shown in Figure 2, the immunotherapy drug L-pampo was administered to the test group, and it was confirmed that the tumor size was suppressed by approximately 52.8% at D22, 12 days after the start of administration, compared to the negative control buffer test group, thereby confirming that the immunotherapy drug L-pampo has an efficacy in suppressing melanoma tumors.
[0106] [Example 3] Confirmation of efficacy of an immuno-oncology agent containing lipopeptide and poly(I:C) in a colorectal cancer mouse model
[0107] [3-1] Creating a Mouse Model
[0108] 5×10 on the right side of 7-week-old female C57BL / 6 mice (Orient Bio, Korea) 4 Tumors were induced in mice by subcutaneously injecting the MC38 mouse colon cancer cell line.
[0110] [3-2] Preparation and Administration of Immunotherapy Agents
[0111] The immunotherapeutic agent L-pampo was prepared by mixing 100 µg of Pam3CSK4 and 80 µg of poly(I:C). A buffer administration group was established as a negative control. The tumor size of the colorectal cancer mouse model constructed in [3-1] was approximately 50 mm 3 When it was reached, 180 µg / dose of L-pampo was administered into the tumor four times at 3-day intervals.
[0113] [3-3] Analysis of Tumor Suppressive Efficacy
[0114] Tumor size was measured at 3-day intervals for all experimental groups. The length and short axis of the tumor were measured [1 / 2 × length of the long axis × (length of the short axis) 2 The tumor size was calculated using ]. The tumor-suppressing efficacy of the immuno-oncology drug was analyzed based on the calculated tumor size.
[0115] The results are shown in Fig. 3. Fig. 3 confirms the tumor-suppressing efficacy of an immunotherapy drug in a colorectal cancer tumor mouse model.
[0116] As shown in Figure 3, compared to the negative control buffer test group, the D19 L-pampo test group showed a potent level of anticancer efficacy with 85.2% tumor suppression 12 days after the start of administration. This demonstrates that the immunotherapy drug L-pampo can strongly inhibit the growth of colorectal cancer tumors.
[0118] [3-4] Analysis of immune cell infiltration within tumors
[0119] Tumors from all mice were collected on D19, 12 days after the start of administration, and immune cell infiltration within the tumors was analyzed using immunofluorescence staining and flow-cytometry analysis.
[0120] To perform immunofluorescence staining, collected mouse tumors were fixed in 1% paraformaldehyde and dehydrated using a 20% sucrose solution. The tumor tissue was frozen by placing it in an OCT (optimal cutting temperature) compound, and the frozen tumor tissue was sliced to a thickness of 50 µm using a cryotome and fixed on a slide. The tumor tissue fixed on the slide was incubated with a blocking solution for 1 hour. CD8 and CD31 antibodies were diluted 1:200 and incubated at 4°C for 24 hours. After incubation, the samples were washed with PBST solution and then incubated with fluorescent antibodies and DAPI solution at room temperature for 2 hours. After mounting, fluorescence images were analyzed using a confocal microscope.
[0121] The results are shown in Figure 4.
[0122] Figure 4 is a figure analyzing the efficacy of immunotherapeutic agents in infiltrating immune cells within tumors using immunofluorescence staining in a colorectal cancer tumor mouse model.
[0123] As shown in Figure 4, the L-pampo test group showed significantly more CD8 T cells (green fluorescence) infiltrated into the tumor than the negative control buffer test group infiltrated with CD8+ T cells. This demonstrates that L-pampo can induce tumor suppression efficacy by immune cells by inducing the infiltration of many CD8 T cells into the tumor.
[0125] To perform flow cytometry, collected mouse tumors were cleaved and treated with collagenase D and DNase I, then incubated at 37°C for 1 hour. The samples were filtered through a 70 µm strainer, lysed with red blood cells, and then filtered again through a nylon mesh. The single-cell suspension was blocked with CD16 / 32 antibodies and stained with cell viable dyes. After staining with fluorescently labeled CD45, CD3, CD8, CD4, Foxp3, and CD25, the results were measured using a CytoFLEX flow cytometer. The measured results were quantitatively compared and analyzed using FlowJo software.
[0126] The results are shown in Figure 5.
[0127] Figure 5 is a figure showing the analysis of the efficacy of an immunotherapy drug in infiltrating immune cells within a tumor using a flow cytometer in a colorectal cancer tumor mouse model.
[0128] As shown in Figure 5, compared to the negative control buffer test group, the L-pampo test group showed a higher infiltration of CD8+ T cells into the tumor. In addition, it was confirmed that the L-pampo test group had significantly lower levels of Treg+ cells, which inhibit T cell activity, within the tumor compared to the negative control group. This demonstrates that L-pampo can induce immune activity capable of killing tumors by infiltrating a large number of CD8+ T cells into the tumor and inhibiting Treg+ cells.
[0130] [3-5] Analysis of tumor-specific cellular immune activity
[0131] Spleens were collected from all mice on D19, 12 days after the start of administration, and tumor-specific immune activity was analyzed using ELISPOT analysis.
[0132] To perform tumor-specific ELISPOT analysis, the collected spleen was strained to separate splenocytes and remove dead cells. Splenocytes and MC39 colorectal cancer cells were mixed and cultured in a 10:1 ratio in a mouse IFN-γ-coded 96-well plate. The cells were incubated with the detection antibody at room temperature for 2 hours, followed by incubation with streptavidin-ALP at room temperature for 1 hour. After incubation, the substrate solution was added to identify spots. The spots were analyzed using Image J software.
[0133] The results are shown in Figure 6.
[0134] Figure 6 is a figure analyzing the induction of tumor-specific cellular immune responses by immunotherapies using ELIPOT analysis in a colorectal cancer tumor mouse model.
[0135] As shown in Figure 6, the L-pampo test group induced significantly more IFN-γ spot formation compared to the negative control buffer test group. Through this, it was confirmed that the intratumoral administration method of the immunotherapy drug L-pampo strongly induces a tumor-specific cellular immune response.
[0137] [3-6] Analysis of Abscopal efficacy in a colorectal cancer mouse model
[0138] To establish the abscopal model, 5×10⁻¹⁰ were placed on the right side of 7-week-old female C57BL / 6 mice (Orient Bio, Korea). 4 5×10⁶ 4 days after subcutaneous injection of MC38 mouse colon cancer cell line 4MC38 colorectal cancer cell lines were injected subcutaneously into the left side to induce tumor formation on both sides. 180 μg / dose of L-pampo prepared in [3-2] above was administered only to the tumor formed on the right side. The tumor-inhibiting efficacy was analyzed by measuring the size of the tumors formed on both sides at 3-day intervals.
[0139] The results are shown in Figure 7.
[0140] Figure 7 is a figure analyzing the efficacy of an immunotherapy drug in a colorectal cancer tumor mouse model.
[0141] As shown in Figure 7, unlike the negative control buffer test group, the L-pampo test group showed a significant reduction in the size of the tumors administered with the immunotherapy L-pampo (right side) as well as the tumors not administered (left side). From this, it was confirmed that when the immunotherapy L-pampo is administered to a tumor, L-pampo can kill tumors not only by causing cancer cell death but also by inducing strong tumor-specific immune activity, which demonstrates that the immunotherapy L-pampo can treat metastatic cancer cells.
[0143] [Example 4] Confirmation of efficacy of an immuno-oncology agent containing lipopeptide and poly(I:C) in a bladder cancer mouse model
[0144] [4-1] Production of a bladder cancer mouse model
[0145] 5×10 on the right side of 7-week-old female C57BL / 6 mice (Orient Bio, Korea) 5 Tumors were induced in mice by subcutaneously injecting the MB49 mouse bladder cancer cell line.
[0147] [4-2] Preparation and Administration of Immunotherapy Agents
[0148] The immunotherapeutic agent L-pampo was prepared by mixing 100 µg of Pam3CSK4 and 80 µg of poly(I:C). A buffer administration group was established as a negative control, and the tumor size of the bladder cancer mouse model constructed in [4-1] was approximately 50 mm 3When it was reached, 180 µg / dose of L-pampo was administered into the tumor four times at 3-day intervals.
[0150] [4-3] Analysis of Tumor Suppressive Efficacy
[0151] Tumor size was measured at 3-day intervals for all experimental groups. The length and short axis of the tumor were measured [1 / 2 × length of the long axis × (length of the short axis) 2 The tumor size was calculated using ]. The tumor-suppressing efficacy of the immuno-oncology drug was analyzed based on the calculated tumor size.
[0152] The results are shown in Figure 8.
[0153] Figure 8 is a figure confirming the tumor-suppressing efficacy of an immunotherapy drug in a bladder cancer mouse model.
[0154] As shown in Figure 8, it was confirmed that the immunotherapy drug L-pampo can strongly inhibit the growth of bladder cancer by confirming that the tumor size of the test group administered the immunotherapy drug L-pampo was suppressed by about 60.3% at D24, 18 days after the start of administration, compared to the negative control buffer test group.
[0156] [Example 5] Confirmation of efficacy of an immuno-oncology agent containing lipopeptide and poly(I:C) in a pancreatic cancer mouse model
[0157] [5-1] Creation of a pancreatic cancer mouse model
[0158] 5×10 on the right side of 8-week-old female C57BL / 6 mice (Orient Bio, Korea) 5 Tumors were induced in mice by subcutaneously injecting KPC mouse pancreatic cancer cell lines.
[0160] [5-2] Preparation and Administration of Immunotherapy Agents
[0161] The immunotherapeutic agent L-pampo was prepared by mixing 100 µg of Pam3CSK4 and 80 µg of poly(I:C). A buffer administration group was established as a negative control, and the tumor size of the pancreatic cancer mouse model constructed in [5-1] was approximately 50 mm 3When it was reached, 180 µg / dose of L-pampo was administered into the tumor four times at 3-day intervals.
[0163] [5-3] Analysis of Tumor Suppressive Efficacy
[0164] Tumor size was measured at 3-day intervals for all experimental groups. The length and short axis of the tumor were measured [1 / 2 × length of the long axis × (length of the short axis) 2 The tumor size was calculated using ]. The tumor-suppressing efficacy of the immuno-oncology drug was analyzed based on the calculated tumor size.
[0165] The results are shown in Fig. 9.
[0166] Figure 9 is a figure confirming the tumor-suppressing efficacy of an immunotherapy drug in a pancreatic cancer mouse model.
[0167] As shown in Figure 9, the test group administered the immunotherapy drug L-pampo showed a reduction in tumor size of approximately 82.9% at D21, 13 days after the start of administration, compared to the negative control buffer test group, confirming that the immunotherapy drug L-pampo can strongly inhibit the growth of pancreatic cancer.
[0169] [Example 6] Confirmation of the efficacy of combination therapy with immune checkpoint inhibitors for an immuno-oncology agent containing lipopeptide and poly(I:C) in a colorectal cancer mouse model
[0170] [6-1] Production of a colorectal cancer mouse model
[0171] 1×10⁻⁶ on the right side of 8-week-old female C57BL / 6 mice (Orient Bio, Korea) 5 Tumors were induced in mice by subcutaneously injecting the MC38 mouse colon cancer cell line.
[0173] [6-2] Preparation and Administration of L-pampo Immunotherapy Agents
[0174] The immunotherapeutic agent L-pampo was prepared by mixing 27.8 µg of Pam3CSK4 and 22.2 µg of poly(I:C). A buffer administration group was established as a negative control, and the tumor size of the colorectal cancer mouse model constructed in [6-1] was approximately 50 mm 3When it was reached, 50 µg / dose of L-pampo was administered into the tumor four times at 3-day intervals.
[0176] [6-3] Administration of immune checkpoint inhibitors
[0177] Mouse PD-1 antibody, an immune checkpoint inhibitor, was purchased from BioXCell. A mouse PD-1 antibody monotherapy group was established as the combination control group, and for the combination group, 200 µg / dose of mouse PD-1 antibody was administered intraperitoneally at 3-day intervals for 4 times when L-pampo was administered intratumorally.
[0179] [6-4] Analysis of Tumor Suppressive Efficacy
[0180] Tumor size was measured at 3-day intervals for all experimental groups. The length and short axis of the tumor were measured [1 / 2 × length of the long axis × (length of the short axis) 2 The tumor size was calculated using ]. The tumor suppression efficacy was analyzed based on the calculated tumor size.
[0181] The results are shown in Figure 10.
[0182] Figure 10 is a figure confirming the efficacy of combining an immunotherapy drug with an immune checkpoint inhibitor in a colorectal cancer mouse model.
[0183] As shown in Figure 10, the test group administered with PD-1 antibodies showed a tumor size reduction of approximately 19.2% at D19 12 days after the start of administration compared to the negative control buffer group. On the other hand, the test group administered with the immunotherapy drug L-pampo showed a tumor size reduction of approximately 60.3% at D19, demonstrating a stronger tumor suppression effect than the immune checkpoint inhibitor PD-1 antibody. Furthermore, the test group administered with both the immunotherapy drug L-pampo and the immune checkpoint inhibitor PD-1 antibody showed a tumor size reduction of approximately 80.7% at D19, with one out of eight tumors showing complete disappearance, confirming that combination therapy with the immunotherapy drug L-pampo and the immune checkpoint inhibitor can demonstrate powerful anticancer efficacy.
[0185] [Example 7] Confirmation of the combined efficacy of lipopeptide and other TLR ligands or saponins of an immuno-oncology agent containing poly(I:C) in a colorectal cancer mouse model
[0186] [7-1] Production of a colorectal cancer mouse model
[0187] 1×10⁻⁶ on the right side of 8-week-old female C57BL / 6 mice (Orient Bio, Korea) 5 Tumors were induced in mice by subcutaneously injecting the MC38 mouse colon cancer cell line.
[0189] [7-2] Preparation and Administration of L-pampo Immunotherapy Agents
[0190] The immunotherapeutic agent L-pampo was prepared by mixing 25 µg of Pam3CSK4 and 20 µg of poly(I:C). A buffer administration group was established as a negative control, and the tumor size of the colorectal cancer mouse model established in [7-1] was approximately 50 mm 3 When it was reached, 45 µg / dose of L-pampo was administered into the tumor four times at 3-day intervals.
[0192] [7-3] Preparation and administration of a combination therapy substance for L-pampo immunotherapy
[0193] A combination therapy was prepared by vortexing the 45 µg / dose L-pampo immunotherapy agent prepared in [7-2] with QS21 (Creative Biolabs) 10 µg / dose or Imiquimod (Invivogen) 10 µg / dose, respectively. This was administered into the tumor four times at 3-day intervals.
[0195] [7-4] Analysis of Tumor Suppressive Efficacy
[0196] Tumor size was measured at 3-day intervals for all experimental groups. The length and short axis of the tumor were measured [1 / 2 × length of the long axis × (length of the short axis) 2 The tumor size was calculated using ]. The tumor suppression efficacy was analyzed based on the calculated tumor size.
[0197] The results are shown in Fig. 11.
[0198] Figure 11 shows the efficacy of combining an immunotherapy drug with other TLR ligands or saponins in a colorectal cancer mouse model.
[0199] As shown in Figure 11a, the test group administered imiquimod (TLR 7 ligand), another TLR ligand, showed approximately 39% inhibition of tumor size on D20, 12 days after the start of administration, compared to the negative control buffer test group. Additionally, the test group administered the saponin QS-21 showed approximately 57% inhibition of tumor size on D20. On the other hand, the test group administered L-pampo showed the most potent tumor growth inhibitory effect among the monotherapy groups, with approximately 78% reduction in tumor size on D20. It was confirmed that in all test groups administered the immunotherapy L-pampo in combination with imiquimod or QS-21, the tumor size on D20 decreased by more than approximately 84%. In addition, as shown in Figure 11b, a similar trend to tumor size inhibition was confirmed in the results of measuring the tumor weight of each test group at D20. Therefore, it was confirmed that combination therapy with the immunotherapy drug L-pampo and other TLR ligands or saponins can show synergistic effects and potent anticancer efficacy.
Claims
Claim 1 A pharmaceutical combination formulation for the prevention or treatment of cancer comprising one or more active ingredients selected from the group consisting of lipopeptides, poly(I:C), immune checkpoint inhibitors, TLR (Toll-like receptor) ligands, and saponins, wherein the lipopeptide is characterized by being one or more selected from the group consisting of Pam3Cys-SKKKK, PHC-SKKKK, Ole2PamCys-SKKKK, Pam2Cys-SKKKK, PamCys(Pam)-SKKKK, Ole2Cys-SKKKK, Myr2Cys-SKKKK, PamDhc-SKKKK, PamCSKKKK, and Dhc-SKKKK, and wherein the cancer is one that overexpresses TLRs relative to normal cells. Claim 2 A pharmaceutical combination formulation according to claim 1, characterized in that the above-mentioned pharmaceutical combination formulation prevents or treats cancer through the activation of a T-cell immune response. Claim 3 delete Claim 4 A pharmaceutical combination formulation according to claim 1, characterized in that the lipopeptide and poly(I:C) have a weight ratio of 0.1 to 10:
1. Claim 5 A pharmaceutical combination formulation according to claim 1, characterized in that the above-mentioned pharmaceutical combination formulation is in an aqueous solution form. Claim 6 A method for generating an immune response against cancer in said individual, comprising the step of administering to an individual other than a human a pharmaceutical combination preparation for the prevention or treatment of cancer, wherein the composition includes one or more active ingredients selected from the group consisting of lipopeptides, poly(I:C), immune checkpoint inhibitors, TLR (Toll-like receptor) ligands, and saponins, wherein the lipopeptides are characterized as being one or more selected from the group consisting of Pam3Cys-SKKKK, PHC-SKKKK, Ole2PamCys-SKKKK, Pam2Cys-SKKKK, PamCys(Pam)-SKKKK, Ole2Cys-SKKKK, Myr2Cys-SKKKK, PamDhc-SKKKK, PamCSKKKK, and Dhc-SKKKK, and wherein the cancer overexpresses TLRs relative to normal cells. Claim 7 A pharmaceutical combination preparation for the prevention or treatment of cancer, comprising a lipopeptide and a poly(I:C) and an immune checkpoint inhibitor as active ingredients, wherein the lipopeptide is one or more selected from the group consisting of Pam3Cys-SKKKK, PHC-SKKKK, Ole2PamCys-SKKKK, Pam2Cys-SKKKK, PamCys(Pam)-SKKKK, Ole2Cys-SKKKK, Myr2Cys-SKKKK, PamDhc-SKKKK, PamCSKKKK, and Dhc-SKKKK, and wherein the cancer overexpresses TLRs relative to normal cells. Claim 8 A combination formulation according to claim 7, wherein the immune checkpoint inhibitor is one or more selected from the group consisting of anti-CTLA4 antibody, anti-PD-L1 antibody, and anti-PD-1 antibody. Claim 9 A combination preparation for the prevention or treatment of cancer, comprising a lipopeptide and a poly(I:C) and TLR (Toll-like receptor) ligand as active ingredients, wherein the lipopeptide is one or more selected from the group consisting of Pam3Cys-SKKKK, PHC-SKKKK, Ole2PamCys-SKKKK, Pam2Cys-SKKKK, PamCys(Pam)-SKKKK, Ole2Cys-SKKKK, Myr2Cys-SKKKK, PamDhc-SKKKK, PamCSKKKK, and Dhc-SKKKK, wherein the cancer overexpresses TLRs relative to normal cells. Claim 10 A combination formulation according to claim 9, characterized in that the TLR (Toll-like receptor) ligand is one or more ligands selected from TLR 1 to 13. Claim 11 A combination preparation for the prevention or treatment of cancer, comprising a lipopeptide and a poly(I:C) and saponin as active ingredients, wherein the lipopeptide is one or more selected from the group consisting of Pam3Cys-SKKKK, PHC-SKKKK, Ole2PamCys-SKKKK, Pam2Cys-SKKKK, PamCys(Pam)-SKKKK, Ole2Cys-SKKKK, Myr2Cys-SKKKK, PamDhc-SKKKK, PamCSKKKK, and Dhc-SKKKK, wherein the cancer overexpresses TLRs relative to normal cells. Claim 12 A combination formulation according to claim 11, characterized in that the saponin is selected from the group consisting of QS21, Quil A, QS7, QS17 and combinations thereof.
Citation Information
Patent Citations
A powerful vaccine composition comprising lipopeptide and poly(i:c) as an adjuvant
KR100900837B1
Adjuvant comprising lipopeptide and poly(i:c), and vaccine composition having improved formulation using same
KR1020140119362A
Compositions of carbohydrate vaccine for inducing immune response in cancer treatment
KR1020160055861A
Compound and method for vaccination and immunisation
KR1020160068751A
Vaccine adjuvant comprising lipopeptide-inserted liposome as an effective ingredient and using thereof
KR1020190018998A
